? Core A The goal of Core A is to provide centralized clinical, analytical and cell-based services and materials to facilitate AML and GBM research across all three Projects. The integration of services and materials in a single Core ensures efficient, standardized and cost-effective handling, characterization and distribution of clinical samples, and provides a common focus for coordinating all Program AML and GBM research. Core A also provides disease-specific research support and important services such as flow cytometry, imaging, cell culture and pathology. These services and materials play critical roles in facilitating Program research to test our Program-wide organizing hypothesis: that the mechanisms driving genetic and epigenetic heterogeneity identify, and may serve as targets for, new and highly effective cancer therapies. Core services: The Core A service plan was developed from the prior period service plan and substantially expanded to provide disease-specific support. Core A will provide centralized support for: ? culture, cryopreservation, and characterization of cells, cell lines and tissue from AML and GBM patients. ? newly developed, tumor-specific Experimental Hematology and Experimental Neurosurgery Core lab support services for Program investigators using these materials to pursue Project Aims. ? mutation typing of recurrent AML/GBM mutations, and for genes of high interest to Program investigators, e.g., the replicative DNA polymerase catalytic subunit genes POLD1 and POLE in Project 1. ? centralized support for drug and RNAi profiling, histopathology, IHC and imaging. The 4 Core Services we will provide to facilitate and support Program research by providing the above are: Core Service 1 ? Integrated clinical and laboratory support services for Program AML research. Core Service 2 ? Integrated clinical and laboratory support services for Program GBM research. Core Service 3 ? Mutation typing and genomic characterization of AML and GBM samples. Core Service 4 ? Centralized support for Program drug/RNAi profiling, imaging and histopathology. Summary: Core A has developed and will continue to support a sophisticated array of support services in addition to supplying high quality, well-characterized AML, GBM and GSC material to support Project research.
? Core A Core A has developed a sophisticated array of support services in addition to supplying high quality, well- characterized AML, GBM and GSC material to support Project research. The integration of services and materials in a single Core ensures efficient, standardized and cost-effective handling, characterization and distribution of clinical samples, and provides a common focus for coordinating all Program AML and GBM research activities.
| Lee, Su-In; Celik, Safiye; Logsdon, Benjamin A et al. (2018) A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat Commun 9:42 |
| Salk, Jesse J; Schmitt, Michael W; Loeb, Lawrence A (2018) Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet 19:269-285 |
| Davis, Luther; Zhang, Yinbo; Maizels, Nancy (2018) Assaying Repair at DNA Nicks. Methods Enzymol 601:71-89 |
| Yu, Ming; Heinzerling, Tai J; Grady, William M (2018) DNA Methylation Analysis Using Droplet Digital PCR. Methods Mol Biol 1768:363-383 |
| Knijnenburg, Theo A; Wang, Linghua; Zimmermann, Michael T et al. (2018) Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23:239-254.e6 |
| Orozco, Javier I J; Knijnenburg, Theo A; Manughian-Peter, Ayla O et al. (2018) Epigenetic profiling for the molecular classification of metastatic brain tumors. Nat Commun 9:4627 |
| Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334 |
| Mikheev, Andrei M; Mikheeva, Svetlana A; Severs, Liza J et al. (2018) Targeting TWIST1 through loss of function inhibits tumorigenicity of human glioblastoma. Mol Oncol 12:1188-1202 |
| Kamath-Loeb, Ashwini S; Zavala-van Rankin, Diego G; Flores-Morales, Jeny et al. (2017) Homozygosity for the WRN Helicase-Inactivating Variant, R834C, does not confer a Werner syndrome clinical phenotype. Sci Rep 7:44081 |
| Oshima, Junko; Sidorova, Julia M; Monnat Jr, Raymond J (2017) Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev 33:105-114 |
Showing the most recent 10 out of 137 publications
